Direct Current Cardioversion: Synchronized Shock Technique for Atrial Fibrillation, Flutter, and Stable Wide-Complex Tachycardia

Direct Current Cardioversion: Synchronized Shock Technique for Atrial Fibrillation, Flutter, and Stable Wide-Complex Tachycardia

📋 Cardiology Procedure 👤 gomdori, MD ⏱ 22 min read 🏥 ACC/AHA 2023 Aligned

Procedure Overview

Direct current (DC) cardioversion is the controlled delivery of synchronized electrical energy across the chest to terminate a re-entrant or ectopic tachyarrhythmia and restore sinus rhythm. Unlike defibrillation (asynchronous shock for VF or pulseless VT), cardioversion delivers the shock at the R wave to avoid landing in the T-wave vulnerable period that can trigger VF. Indications include hemodynamically unstable atrial fibrillation, atrial flutter, supraventricular tachycardia, monomorphic ventricular tachycardia with a pulse, and elective rhythm control of stable AF after appropriate anticoagulation. Standard biphasic energies are 120-200 J (often 200 J) for AF, 50-100 J for atrial flutter and SVT, and 100 J for stable monomorphic VT. Electrode placement is typically antero-lateral (right infraclavicular + left mid-axillary) or antero-posterior; AP is often more effective for AF. Procedural sedation with etomidate, midazolam plus fentanyl, or propofol is delivered with continuous SpO2, ECG, and BP monitoring. Anticoagulation rules are critical: AF or atrial flutter of duration ≥48 hours or unknown duration requires either ≥3 weeks of therapeutic anticoagulation OR a transesophageal echocardiogram excluding LA appendage thrombus before cardioversion, and ≥4 weeks of anticoagulation after. Success rates exceed 90 percent for AF and 95 percent for atrial flutter with biphasic devices, with stroke risk under 1 percent when anticoagulation rules are followed.

90-95%First-Shock Success (Biphasic)
120-200JAF Initial Energy
50-100JAtrial Flutter / SVT
<1%Stroke Risk (Anticoag-compliant)

S1. Indications and Contraindications

Emergency cardioversion (unstable patient)

Per ACLS, immediate synchronized cardioversion is indicated for any tachyarrhythmia with serious signs or symptoms attributable to the rhythm: hypotension (SBP <90 mmHg or evidence of shock), acutely altered mental status, ischemic chest pain, acute heart failure or pulmonary edema. Sedation should be considered if the patient is conscious but is not allowed to delay cardioversion in critically unstable patients.

  • Unstable atrial fibrillation with rapid ventricular response causing hemodynamic compromise.
  • Unstable atrial flutter with 1:1 conduction (typically 250-300 bpm ventricular rate).
  • Unstable supraventricular tachycardia refractory to vagal maneuvers and adenosine.
  • Stable monomorphic ventricular tachycardia after failure of antiarrhythmics, or hemodynamically unstable VT with a pulse.
  • Pulseless VT or VF—use defibrillation (asynchronous), not cardioversion.
  • Polymorphic VT (e.g., torsades de pointes)—use defibrillation; cardioversion sync mode often fails to detect QRS reliably.

Elective cardioversion (stable patient)

Elective rhythm control may be attempted in selected patients with persistent atrial fibrillation, atrial flutter, or SVT after appropriate anticoagulation and rate control. Common scenarios:

  • First-detected episode of AF in a young patient or following correction of a reversible trigger (post-cardiac surgery, post-COVID, electrolyte derangement).
  • Persistent AF with symptoms despite rate control (palpitations, exercise intolerance, fatigue, dyspnea).
  • Atrial flutter not amenable to or pending catheter ablation of cavotricuspid isthmus.
  • Pre-procedure rhythm conversion before elective procedures requiring sinus rhythm (e.g., AV node ablation prep).
  • Failure of pharmacologic cardioversion (e.g., flecainide pill-in-pocket, ibutilide, amiodarone loading).

Contraindications

TypeContraindicationReason
AbsoluteDigitalis toxicity with arrhythmiaCardioversion can precipitate refractory VF
AbsoluteUntreated severe hypokalemia (K <3.0 mEq/L)Increased risk of post-shock VF and asystole
AbsoluteKnown LA or LV thrombus on imagingHigh stroke risk; treat with ≥3-4 wk anticoagulation first
RelativeAF >1 year duration with severe LA enlargement (>5 cm)Low success and high recurrence; consider rate control or ablation
RelativeMultifocal atrial tachycardiaUnderlying lung/metabolic disease must be treated; rarely responds
RelativeSevere sinus node dysfunction without pacemakerRisk of post-cardioversion bradyasystole
RelativeInadequate anticoagulation in AF/flutter ≥48 hStroke risk; complete anticoag or perform TEE first
RelativeHyperthyroidism (untreated)High recurrence; treat thyroid disease first

S2. Pre-Procedure Anticoagulation Rules

Stroke is the most feared complication of cardioversion, occurring in 1-7 percent of patients without proper anticoagulation but in less than 1 percent when guidelines are followed. Cardioversion converts a fibrillating atrium back to organized contraction; if a thrombus has formed in the left atrial appendage during the AF episode, restoration of mechanical contraction can dislodge it.

The “≥48 hour rule”

ScenarioPre-CardioversionPost-Cardioversion
AF/flutter <48 hours, hemodynamically stableHeparin or DOAC initiated; no mandatory wait≥4 weeks anticoagulation (longer if CHA₂DS₂-VASc indicates lifelong therapy)
AF/flutter ≥48 hours OR unknown duration—conventional approach≥3 weeks therapeutic anticoagulation (warfarin INR 2-3, or therapeutic DOAC) confirmed before procedure≥4 weeks anticoagulation (lifelong if CHA₂DS₂-VASc ≥2 men, ≥3 women)
AF/flutter ≥48 hours OR unknown—TEE-guided approachTEE within 24-48 h of cardioversion confirming no LA appendage thrombus; therapeutic anticoagulation initiated before TEE≥4 weeks anticoagulation (lifelong if CHA₂DS₂-VASc indicates)
AF/flutter ANY duration with hemodynamic instabilityCardiovert immediately; initiate anticoagulation as soon as possible after≥4 weeks anticoagulation (lifelong if CHA₂DS₂-VASc indicates)
SVT (e.g., AVNRT, AVRT)Anticoagulation NOT routinely requiredNone unless other indication
Stable monomorphic VTAnticoagulation NOT routinely requiredAddress structural heart disease, ICD evaluation

DOAC documentation requirements

For the conventional approach using DOACs, the patient must have received uninterrupted, therapeutic-dose DOAC for ≥3 consecutive weeks before cardioversion with documented adherence. Unlike warfarin, DOACs cannot be confirmed by routine laboratory testing in real-time, so adherence relies on patient/pharmacy verification. Missed doses of more than 24 hours invalidate the 3-week window.

TEE-guided cardioversion strategy

The TEE-guided approach (ACUTE trial) shortens time to cardioversion when delaying 3 weeks is undesirable (severe symptoms, plan for early electrophysiology study, hemodynamic concerns). Procedure:

  • Initiate therapeutic anticoagulation (heparin gtt, enoxaparin 1 mg/kg SC q12h, or DOAC).
  • Perform TEE evaluating left atrial appendage with multi-plane views and color Doppler. No thrombus → proceed to cardioversion within 24-48 h.
  • If thrombus identified, postpone cardioversion, treat with ≥3-4 weeks anticoagulation, repeat TEE, and reassess.
  • Continue anticoagulation post-cardioversion for ≥4 weeks regardless of TEE result.

Pre-procedure checklist

📋 Pre-cardioversion checklist

  • Confirmed indication and informed consent (risks: stroke 1%, skin burn 5-15%, transient arrhythmia, sedation complications).
  • Anticoagulation status verified—INR, dose timing, duration; or TEE result documented.
  • NPO status—8 hours solid food, 2 hours clear liquids; exception for emergent unstable cardioversion.
  • Recent ECG confirming current rhythm; recent K+, Mg²⁺, digoxin level if applicable; correct K+ to ≥4.0 mEq/L and Mg²⁺ to ≥2.0 mg/dL before elective shock.
  • IV access, continuous ECG monitoring, SpO2, BP cuff (cycling q3 min during procedure).
  • Crash cart, defibrillator, intubation equipment, suction, reversal agents at bedside (naloxone, flumazenil).
  • Anesthesia or sedation provider with cardiac arrest training.
  • Personnel—operator, sedation provider, RN, technician/respiratory therapist.
Direct Current Cardioversion — Cardiac Conduction Cardiac conduction system from SA node to Purkinje fibers Direct Current Cardioversion — Cardiac Conduction SA SA Node AV AV Node HIS Bundle of His LBB Left Bundle Branch RBB Right Bundle Branch PURK Purkinje Fibers SA→AV: 50ms | AV delay: 100ms | His→Purkinje: 40ms | Total: ~200ms
Direct Current Cardioversion — Cardiac Conduction

S3. Equipment and Patient Setup

Equipment checklist

  • Biphasic defibrillator/cardioverter—biphasic technology achieves higher first-shock success at lower energies than older monophasic devices, which are largely obsolete.
  • Self-adhesive defibrillation pads (combo pads with pacing capability preferred)—two pads, one for each electrode position.
  • 3- or 5-lead ECG monitor with the cardioverter’s sync display (the device shows R-wave markers when sync is engaged).
  • Bag-valve-mask, oxygen, suction, advanced airway equipment.
  • Sedation medications, reversal agents, code cart.
  • Ultrasound for IV access if difficult.

Pad placement

Two configurations are accepted; antero-posterior may be marginally more effective for atrial fibrillation but evidence is mixed:

ConfigurationPad PositionsBest For
Antero-lateral (AL)Anterior pad: right infraclavicular (2nd intercostal space, mid-clavicular). Lateral pad: left mid-axillary line (5th-6th intercostal space, V6 lead position).Default for VT/SVT/atrial flutter; more familiar setup
Antero-posterior (AP)Anterior pad: left precordium (V3-V4 area). Posterior pad: between left scapula and spine, paraspinal.AF (slight efficacy advantage in some studies); patients with implanted devices
DC cardioversion pad placement configurations Diagram comparing antero-lateral and antero-posterior pad placements on the chest Pad Placement Configurations Antero-lateral A L R infraclav + L mid-axilla Antero-posterior A (Posterior pad behind scapula) L precordium + L paraspinal Both achieve 90-95% success AP slightly better for AF
Figure 1. Antero-lateral vs antero-posterior pad placement; AP marginally favored for AF.

Special pad placement considerations

  • Pacemaker or ICD—keep pads ≥8 cm (3 inches) from the device; AP placement preferred. Interrogate the device after cardioversion to ensure proper function.
  • Female patients—lateral pad placement to the side of breast tissue, on the lateral chest wall, not on the breast itself.
  • Hirsute chest—rapidly clip (do not shave, avoiding skin abrasion) to ensure pad-to-skin contact; high impedance from hair degrades shock delivery.
  • Wet skin—dry thoroughly before pad placement; conductive arc from wet skin to operator can cause injury.
  • Pediatric patients—use pediatric pads (under 10 kg or under 1 year); place AP if AL pads contact each other.

Sedation regimens

Cardioversion is painful and requires moderate to deep sedation. Three commonly used regimens:

RegimenDoseOnset / DurationNotes
Etomidate0.1-0.3 mg/kg IV bolus30-60 sec / 5-10 minHemodynamically neutral; preferred in cardiac dysfunction; myoclonus, brief adrenal suppression
Midazolam + FentanylMidaz 1-2 mg IV + Fentanyl 25-50 mcg IV2-3 min / 30-60 minReversible (flumazenil, naloxone); longer recovery; respiratory depression
Propofol0.5-1 mg/kg IV bolus30-60 sec / 5-10 minHypotension common; preferred when anesthesia provider available; rapid recovery
Ketamine (alternative)0.5-1 mg/kg IV1-2 min / 10-15 minMaintains hemodynamics; emergence reactions; may increase HR/BP

⚠️ Sedation safety reminders

Pre-oxygenate with 100% O2 via non-rebreather for 3 minutes before sedation. Maintain SpO2 ≥94% throughout. Have suction immediately available; many patients vomit during shock. Continuous capnography is recommended for moderate-deep sedation per Joint Commission. Reverse with naloxone (0.04-0.4 mg IV) for opioid-induced respiratory depression or flumazenil (0.2 mg IV) for benzodiazepine; propofol and etomidate have no specific reversal—support airway and ventilation until effect resolves (5-10 min).

S4. Step-by-Step Technique

Pre-shock confirmation

  1. Confirm patient identity, indication, anticoagulation status, NPO status—surgical safety pause.
  2. Confirm rhythm on continuous monitor matches the indication; print 12-lead ECG documenting pre-cardioversion rhythm.
  3. Confirm K+, Mg²⁺ corrected; verify no digoxin toxicity.
  4. Apply pads in chosen configuration; confirm good skin contact (no air, no hair, no wetness).
  5. Connect monitor leads from cardioverter to patient; verify clear QRS tracking on the cardioverter screen.
  6. Pre-oxygenate with NRB at 15 L/min for 3 minutes.
  7. Administer sedation; wait for adequate sedation (loss of consent response or strong painful stimulus).

Synchronization—the critical step

Press the SYNC button on the cardioverter. The device should display markers (often arrows or asterisks) on every R wave indicating successful synchronization. Verify that the markers are on R waves and not on T waves or pacemaker spikes. If sync is unstable (artifact, low R-wave amplitude), increase ECG gain, change the lead viewed, or reposition pads. Failure to verify synchronization is a critical error that can deliver shock during the T-wave vulnerable period and induce VF.

🚨 Synchronization rules

SYNC must be confirmed before EVERY shock. Many devices automatically revert to asynchronous (defibrillation) mode after each delivered shock to allow immediate VF treatment. You must press SYNC again before each subsequent cardioversion attempt.

If the rhythm degenerates to VF after a sync attempt, immediately turn OFF sync and deliver an unsynchronized defibrillation shock (200 J biphasic).

Cardioversion is contraindicated for polymorphic VT/torsades—use defibrillation. Sync mode often cannot reliably identify QRS in polymorphic rhythms.

Energy selection and escalation

RhythmInitial Energy (Biphasic)EscalationMaximum
Atrial fibrillation200 J (some 120-150 J)200 → 300 → 360 J360 J
Atrial flutter50-100 J100 → 150 → 200 J360 J
SVT (AVNRT, AVRT)50-100 J100 → 150 → 200 J360 J
Monomorphic VT (with pulse)100 J150 → 200 → 300 → 360 J360 J
Polymorphic VT (e.g., torsades) — DEFIBRILLATION not cardioversion200 J unsynchronized200 → 300 → 360 J360 J
Pulseless VT/VF — DEFIBRILLATION not cardioversion200 J unsynchronized200 → 300 → 360 J360 J

Shock delivery sequence

  1. Charge the device to selected energy; the cardioverter audible tone confirms charging.
  2. Loud verbal “ALL CLEAR” warning—ensure no one is touching the patient or bed; visually confirm all team members are clear.
  3. Discontinue oxygen flow over the chest (move NRB or BVM ≥1 m from patient pads to prevent fire from arc) for the brief moment of shock.
  4. Press and hold the SHOCK button—the device delivers the shock at the next R wave (may be a 0.5-1 second delay); do not release until shock is delivered (the screen confirms delivery).
  5. Reassess rhythm immediately after the shock—print rhythm strip, check pulse and blood pressure; verify return to sinus or persistent arrhythmia.
  6. If unsuccessful, re-engage SYNC, escalate energy, repeat; consider repositioning pads (AL → AP), adjusting impedance (firm pad pressure), or pretreating with ibutilide 1 mg IV over 10 min for refractory AF.
  7. If VF develops, immediately switch to asynchronous defibrillation, follow ACLS algorithm.

Verification of success

Successful cardioversion is defined as restoration of sinus rhythm for at least 30 seconds. Print 12-lead ECG within 5 minutes of conversion and at 1 hour post-procedure. Document rhythm strip from before, during, and after each shock.

S5. Complications and Management

ComplicationFrequencyRisk FactorsManagement
Skin burn / erythema5-15%Hairy chest, poor pad contact, high impedance, multiple shocksTopical hydrocortisone, aloe; healed in 1-2 weeks; reposition pads in future
Transient bradyarrhythmia / asystole1-3%Sinus node dysfunction, beta-blocker, digoxin useAtropine 0.5-1 mg IV; transcutaneous pacing; usually resolves within 1-2 min
Embolic stroke / TIA0.3-1% (anticoag-compliant); 1-7% if notAF/flutter ≥48 h without anticoagulation, LA thrombus on TEEAcute stroke pathway: NIH stroke scale, CT/CTA, alteplase or thrombectomy if eligible
Ventricular fibrillation<1%Failed sync (T-wave shock), digoxin toxicity, severe hypoKImmediate defibrillation 200 J; ACLS algorithm
Hypotension3-10%Sedation, propofol, baseline LV dysfunctionIV fluids, pressors (norepinephrine), reversal of sedative
Respiratory depression5-10%Sedation overdose, opioid + benzo comboBag-valve-mask ventilation, naloxone or flumazenil reversal
Pulmonary edema (transient)1-3%LV dysfunction, conversion in heart failureIV furosemide 40 mg, BiPAP, oxygen
Tachy-brady syndrome unmasked2-5%Sick sinus syndrome with prior tachyarrhythmia compensationPermanent pacemaker if symptomatic; long-pause pre-discharge monitoring
Myocardial enzyme rise (transient)10-20%Multiple high-energy shocks, AP placementSelf-limited, no clinical consequence; not myocardial infarction
Recurrence of arrhythmia30-50% at 1 year (AF)LA enlargement, AF duration, HTN, OSARhythm control with antiarrhythmics, catheter ablation, or accept rate control

Managing failed cardioversion

If sinus rhythm is not restored after 3 escalating shocks at maximum energy with appropriate pad placement, options include:

  • Pretreat with ibutilide 1 mg IV over 10 min—lowers defibrillation threshold; can be repeated once after 10 min if needed; monitor for QTc prolongation and torsades for 4 hours.
  • Switch pad position AL → AP (or vice versa); apply manual pressure on pads to reduce impedance.
  • Pretreat with amiodarone 150 mg IV bolus then infusion; may convert pharmacologically over hours and improve future shock success.
  • Optimize K+ to ≥4.5 mEq/L and Mg²⁺ to ≥2.5 mg/dL for refractory cases.
  • Defer cardioversion and accept rate control; consider catheter ablation referral.
  • Repeat in 1-3 months after antiarrhythmic loading (sotalol, dofetilide) to improve success.

🚨 When to escalate—electrophysiology consultation

Mandatory EP consultation for: failed cardioversion despite optimal technique; recurrent AF/flutter requiring rhythm control; suspected accessory pathway tachycardia (Wolff-Parkinson-White); polymorphic VT requiring ICD evaluation; consideration of catheter ablation (pulmonary vein isolation for AF, cavotricuspid isthmus ablation for flutter, AVNRT slow pathway ablation).

Anesthesia consultation for: high-risk sedation candidates (severe heart failure, COPD with CO2 retention, difficult airway, BMI >40, history of awareness during sedation).

Stroke neurology emergency activation for any post-cardioversion focal neurologic deficit—time is brain, transfer immediately to CT and consider tPA within window.

Direct Current Cardioversion — Procedure Steps Surgical stepper: Direct Current Cardioversion — Procedure Steps Direct Current Cardioversion — Procedure Steps 1 Shock delivered but AF persists 2 Reposition pads to AP if anterior-anteri or used; max biphasic 360J 3 Pre-treat with ibutilide 1mg IV over 10 min OR amiodarone 150mg IV → re-shock 4 Post-shock bradyasystole / pause >5 sec 5 Atropine 0.5 mg IV; transcutaneous pacin g if persistent; isoproterenol PRN 6 Skin burns at pad sites — common with mu ltiple shocks 7 Cool compress + topical aloe; avoid furt her shocks at same site 8 Thromboembolic event (stroke / systemic embolism) — anticoag failure
Direct Current Cardioversion — Procedure Steps

Procedural Experience: DCCV — Anteroposterior Pads, TEE-First for Unknown Duration AF, and Biphasic 200J Starting Energy

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.)In experienced practice, the technique has converged on three concrete shifts: (1) anteroposterior pad placement is preferred over anterolateral for AF (better current vector through the atria, higher first-shock success); (2) TEE-guided cardioversion is the default for AF with unknown duration or duration > 48 hours — substantially reduces stroke risk vs traditional 3-weeks-of-anticoagulation pathway; (3) biphasic 200 J as starting energy for AF cardioversion (vs older 100 J) — higher first-shock success without increased complications. The “100 J starting energy” tradition has been retired by recent guidelines.

Anteroposterior pad placement preferred for AF

Pad placement options: anterolateral (RA-LV apex) vs anteroposterior (anterior chest-posterior). For AF cardioversion, anteroposterior placement creates a current vector that passes more directly through the atrial myocardium, improving first-shock success rate by ~10 percentage points absolute. For VT/VF/atrial flutter, either configuration is acceptable. The anterior pad is placed in the right parasternal area at the 2nd-3rd intercostal space; the posterior pad between the left scapula and spine. For obese patients, larger pads (smaller impedance) and anteroposterior orientation both help.

TEE-guided cardioversion for unknown duration AF

For AF with documented duration < 48 hours, immediate cardioversion is acceptable without anticoagulation. For unknown duration or > 48 hours, two pathways: (a) 3 weeks of therapeutic anticoagulation before cardioversion + 4 weeks after; OR (b) TEE-guided immediate cardioversion + 4 weeks of anticoagulation after (ACUTE trial 2001). Clinicians prefer TEE-guided in experienced practice — saves the 3-week pre-procedure waiting period, identifies LA thrombus before cardioversion (~5-10% of AF patients), and avoids the dropout that occurs during 3-week anticoagulation waiting. After successful cardioversion: lifelong anticoagulation per CHA2DS2-VASc score, NOT just 4 weeks.

Biphasic 200J starting energy for AF — not 100J

Older guidelines started AF cardioversion at 100 J biphasic. Recent evidence supports starting at 200 J for higher first-shock success (~75-80% vs ~50-60% at 100 J) without increased complications. Experienced clinicians start at 200 J biphasic for AF; escalate to 300 J then 360 J if needed (max 3 shocks per session). Atrial flutter starts at 50-100 J (more responsive). Stable wide-complex tachycardia 100 J. Pediatric: 0.5-1 J/kg starting, doubling on subsequent shocks. Synchronization marker confirmed on the R-wave before each shock — defibrillator should display “SYNC” indicator and timing marker.

Procedural sedation: propofol or etomidate with airway-ready team

DCCV requires deep procedural sedation. The preferred agents: propofol 1-1.5 mg/kg IV bolus (rapid onset, short duration, hemodynamically neutral in healthy patients but causes hypotension in elderly/hypovolemic) OR etomidate 0.1-0.3 mg/kg IV (more hemodynamically stable, especially in elderly or critically ill). Avoid midazolam alone (inadequate sedation depth, prolonged duration). Airway-management trained operator (anesthesia or proceduralist with airway skills); pre-oxygenation with 100% O2; capnography monitoring; resuscitation equipment immediately available. Post-procedure: monitor sedation reversal, airway, hemodynamics.

Illustrative Scenario: Persistent AF DCCV with TEE-Guided Pathway

A man in his late fifties with hypertension and type 2 diabetes (CHA2DS2-VASc 2) presented with persistent atrial fibrillation documented for 3 weeks (palpitations, mild dyspnea, no chest pain). HR 110, BP 138/82, SpO2 96% on room air. ECG confirmed AF with rapid ventricular response. Echocardiogram: LVEF 60%, mild LA enlargement (LAVi 38 mL/m²), no significant valve disease. Hospital course: rate-controlled with metoprolol 25 mg BID for symptom relief; initiated apixaban 5 mg BID for stroke prevention. 4 weeks of documented apixaban compliance (verified by pharmacy refill records and patient diary). Pre-DCCV TEE: no LA appendage thrombus, no significant valve abnormality, normal spontaneous echo contrast — proceeding with cardioversion was safe. DCCV performed in monitored cardiology procedure room: propofol 100 mg IV bolus for deep sedation; airway-trained operator present, capnography monitored. Anteroposterior pad placement (anterior right 2nd-3rd ICS, posterior left infrascapular). Defibrillator synchronized to R-wave (SYNC marker confirmed). First shock biphasic 200 J — converted to sinus rhythm. Post-procedure ECG: NSR rate 70 bpm. 4-hour monitored observation: stable, no recurrence. Discharged same day. Long-term plan: lifelong apixaban (CHA2DS2-VASc 2), metoprolol 25 mg BID for rate control if AF recurs, cardiology follow-up at 4 weeks. At 4-week follow-up: maintained sinus rhythm.

The takeaway: TEE-guided pathway shortened pre-procedure waiting + verified no LA thrombus + enabled same-admission cardioversion. Anteroposterior pad placement + biphasic 200 J starting energy + propofol sedation with airway-trained team delivered first-shock success and uneventful recovery. Lifelong anticoagulation post-cardioversion is per CHA2DS2-VASc, NOT just 4 weeks — common misconception.

Four Procedural Deviations Experienced Clinicians Now Default To

  1. Anteroposterior pad placement for AF (anterolateral acceptable for VT/VF/flutter). Current vector through atrial myocardium → ~10% absolute improvement in first-shock success vs anterolateral.
  2. TEE-guided cardioversion for AF with unknown duration or > 48 hours. Saves 3 weeks of pre-procedure waiting + identifies LA thrombus before shock (~5-10%) + avoids anticoagulation-waiting dropout. ACUTE trial 2001 evidence base.
  3. Biphasic 200 J starting energy for AF (not 100 J); 50-100 J for atrial flutter; 100 J for stable wide-complex. First-shock success 75-80% at 200 J vs 50-60% at 100 J. Escalate 300 J → 360 J as needed; max 3 shocks per session.
  4. Procedural sedation with propofol or etomidate + airway-trained team + capnography monitoring. Propofol 1-1.5 mg/kg (healthy patients) or etomidate 0.1-0.3 mg/kg (elderly/critically ill). Lifelong anticoagulation post-cardioversion per CHA2DS2-VASc, NOT just 4 weeks.
DCCV bedside protocol: TEE pathway + pad placement + biphasic energy selection + sedation Two-panel diagram showing DCCV TEE-guided pathway selection and procedural technique with biphasic energy by rhythm. DCCV: TEE Pathway + Anteroposterior Pads + Biphasic 200J Panel A: AF Pre-DCCV Pathway AF duration < 48 hours: Immediate DCCV without anticoagulation Post: anticoag per CHA2DS2-VASc AF > 48 h or unknown duration: Option A: 3 wks anticoag → DCCV → 4 wks post Option B: TEE-guided immediate DCCV → 4 wks post (ACUTE trial) TEE-guided preferred (experienced practice): Saves 3 wks waiting + finds LA thrombus 5-10% Avoids anticoag-waiting dropout ⚠️ Lifelong anticoag per CHA2DS2-VASc NOT just 4 weeks post-DCCV — common misconception Panel B: Technique + Energy Pad placement for AF: ANTEROPOSTERIOR preferred (R 2-3 ICS / L scap) ~10% better first-shock success Biphasic energy by rhythm: AF: 200 J → 300 J → 360 J (max 3 shocks) Aflutter: 50-100 J; VT: 100 J; SVT: 50-100 J SYNC marker on R-wave confirmed Synchronized shock for tachy w/ pulse Unsynchronized for VF/pulseless VT Procedural sedation: Propofol 1-1.5 mg/kg (healthy) Etomidate 0.1-0.3 mg/kg (elderly/critically ill) Airway-trained team + capnography Pre-oxygenation 100% O2 + resus ready Pediatric: 0.5-1 J/kg starting, doubling subsequent • Larger pads + AP orientation for obese patients (lower impedance, better current vector) • Post-procedure: 4-hour observation; complications (rare): skin burn, transient arrhythmia, stroke (if inadequate anticoag)

S6. Post-Procedure Care, Pearls, and Pitfalls

Immediate post-procedure

  • Monitor on telemetry for ≥1 hour after sedation has worn off; document return to baseline mental status.
  • Print 12-lead ECG at 5 min and 1 hour post-cardioversion to confirm sustained sinus rhythm.
  • Vital signs every 15 min × 4, then every 30 min × 2.
  • NPO until fully alert; resume diet 1-2 hours after sedation wear-off.
  • Restart anticoagulation (if held) and continue uninterrupted for ≥4 weeks—even if patient remains in sinus rhythm.
  • Skin inspection at pad sites; document any erythema or burn.

Discharge planning (outpatient elective cardioversion)

  • Discharge same-day if stable for ≥1 hour, alert, eating, and ambulating.
  • No driving for 24 hours post-sedation; arrange transport home.
  • Continue therapeutic anticoagulation for ≥4 weeks; lifelong if CHA₂DS₂-VASc ≥2 men, ≥3 women.
  • Continue beta-blocker or non-DHP CCB for rate control if AF recurs.
  • Consider antiarrhythmic for rhythm maintenance (flecainide for structurally normal heart; amiodarone, sotalol, dofetilide for structural heart disease).
  • Cardiology follow-up within 2-4 weeks; ECG and rhythm assessment.
  • Emergency return precautions: palpitations, syncope, focal neurologic symptoms, chest pain.

Pearls and pitfalls

💎 Pearl 1

Always verify SYNC before every shock. The cardioverter must show R-wave markers when sync is engaged. Many devices revert to asynchronous mode after each shock, so re-engage SYNC before any repeat attempt. Failure to sync can deliver the shock during the T-wave vulnerable period and trigger VF.

⚠️ Pitfall 1

Do not cardiovert AF/flutter ≥48 hours without anticoagulation or TEE. Stroke risk approaches 7 percent without prophylaxis; 1 percent with proper anticoagulation. The only exception is hemodynamic instability requiring emergent shock—initiate anticoagulation immediately afterward and continue for ≥4 weeks regardless.

💎 Pearl 2

Start AF cardioversion at 200 J biphasic, not 120 J. While 120-150 J succeeds in many cases, beginning at 200 J reduces total energy delivered, shortens procedure time, and minimizes pad-related skin injury. The exception is small body habitus or cardioversion pacing capability with stepwise titration.

⚠️ Pitfall 2

Polymorphic VT requires defibrillation, not cardioversion. Sync mode may fail to detect a consistent R wave in polymorphic rhythms, leaving the device unable to deliver a shock. For torsades de pointes or any polymorphic VT, deliver an asynchronous 200 J biphasic defibrillation immediately.

💎 Pearl 3

Antero-posterior pad placement is more effective for AF. Several randomized trials show 2-10 percent absolute increase in first-shock success with AP versus AL placement for AF. AP is particularly preferred in patients with implanted devices, large body habitus, or after a failed AL attempt.

⚠️ Pitfall 3

Do not cardiovert in suspected digoxin toxicity. Cardioversion in the digoxin-toxic patient can trigger refractory ventricular fibrillation and asystole. Check digoxin level, serum K+ and Mg²⁺ before elective cardioversion in any patient on digoxin; treat hyperkalemia and use digoxin-specific Fab fragments (DigiFab) before any shock if toxicity is suspected.

💎 Pearl 4

Restart anticoagulation post-cardioversion regardless of TEE result or short AF duration. Atrial mechanical “stunning” persists for 2-4 weeks after cardioversion even when electrical sinus rhythm is restored, allowing thrombus formation in the appendage. Continue therapeutic anticoagulation for ≥4 weeks after every successful cardioversion; lifelong if CHA₂DS₂-VASc indicates.

⚠️ Pitfall 4

Do not omit pre-procedure potassium and magnesium correction. Hypokalemia (K <3.5) and hypomagnesemia (Mg <1.8) lower the VF threshold and reduce cardioversion success. Replete to K+ ≥4.0 and Mg²⁺ ≥2.0 mg/dL before elective procedures; in emergent unstable cardioversion, replete during/after the shock.

Frequently asked questions

Cardioversion is a synchronized shock delivered in coordination with the R wave to convert an organized but abnormal rhythm such as atrial fibrillation, atrial flutter, supraventricular tachycardia, or monomorphic ventricular tachycardia with a pulse. Defibrillation is an unsynchronized shock used for ventricular fibrillation, pulseless ventricular tachycardia, or polymorphic ventricular tachycardia where no organized R wave can be reliably identified. Synchronization avoids delivering the shock during the T-wave vulnerable period, which would trigger ventricular fibrillation.
Standard biphasic energies are 120 to 200 joules (often 200 J as initial energy) for atrial fibrillation, 50 to 100 J for atrial flutter and supraventricular tachycardia, and 100 J for monomorphic ventricular tachycardia with a pulse. If the first shock fails, energy is escalated stepwise to a maximum of 360 J. Older monophasic devices required higher energies and have largely been replaced by biphasic units.
Atrial fibrillation or flutter of duration 48 hours or more, or unknown duration, requires either at least 3 weeks of therapeutic anticoagulation before cardioversion or a transesophageal echocardiogram excluding left atrial appendage thrombus. After successful cardioversion, all patients require at least 4 weeks of anticoagulation because of post-cardioversion atrial mechanical stunning. Lifelong anticoagulation is indicated if CHA₂DS₂-VASc score is 2 or higher in men or 3 or higher in women.
Biphasic DC cardioversion successfully restores sinus rhythm in approximately 90 to 95 percent of atrial fibrillation cases on the first or second shock. Atrial flutter has even higher success rates of 95 to 98 percent. However, recurrence of atrial fibrillation occurs in approximately 30 to 50 percent of patients within 1 year, depending on left atrial size, AF duration, and underlying conditions. Antiarrhythmic medications or catheter ablation may be needed for long-term rhythm maintenance.
Etomidate 0.1 to 0.3 mg per kilogram IV bolus is preferred in patients with cardiac dysfunction because it is hemodynamically neutral. Propofol 0.5 to 1 mg per kilogram IV provides rapid onset and recovery but commonly causes hypotension, making it suitable when an anesthesia provider is present. The combination of midazolam 1 to 2 mg with fentanyl 25 to 50 micrograms IV is reversible with flumazenil and naloxone but produces longer recovery times. All regimens require continuous SpO2, ECG, BP monitoring and immediate availability of airway equipment and reversal agents.
The most serious complications are embolic stroke (less than 1 percent if anticoagulation rules are followed; up to 7 percent if not) and induction of ventricular fibrillation by failure to synchronize the shock to the R wave. Other complications include skin burns at pad sites (5 to 15 percent), transient bradyarrhythmia or asystole especially in patients with sinus node dysfunction (1 to 3 percent), hypotension from sedation (3 to 10 percent), and respiratory depression. Pre-procedure anticoagulation, electrolyte correction, and verified synchronization minimize these risks.
Yes, but with precautions. Pads should be placed at least 8 centimeters (3 inches) from the implanted device, and antero-posterior placement is preferred to minimize current flow through the device. The device should be interrogated after the procedure to confirm proper sensing, pacing thresholds, and battery integrity. ICDs should be temporarily disabled with a magnet or programmer during cardioversion to prevent the ICD from sensing the artifact and delivering an unintended shock. Electrophysiology consultation is recommended for cardioversion in patients with cardiac implantable devices.

Leave a Reply

Your email address will not be published. Required fields are marked *